Chief Operating Officer | Partner
Expertise 
Toxicology
Non-clinical development
Clinical development
GLP
Immunotoxicology
Business development
Project management
Immunology
Diagnostics
Drug metabolism
Interim management
Toxicokinetics
Safe starting dose
First-in-human
Non-clinical development strategy
Women’s health
Infectious diseases
Autoimmune diseases
Outsourcing strategy
Biotechnology
Biography 

As of November 23, 2016 3D-PharmXchange has appointed François van Och as Chief Operating Officer (COO)  

Recent projects involved project management for Biocartis’ fully integrated molecular diagnostics platform Idylla and toxicology support for the development of a BTK inhibitor to support initiation of a clinical trial in end-stage cancer patients.

Prior to joining 3D-PharmXchange, he worked in the pharmaceutical industry for 10 years in various positions at Organon N.V., Schering-Plough and Merck. During this time he gained broad experience and skills in leadership in drug discovery and development both as line- and project manager in the area of toxicology, DMPK, biopharmaceutics and early clinical research. His latest position at Merck was compound director non-clinical development.  

François studied Biological Sciences at the University of Utrecht, The Netherlands and obtained his Ph.D. on Immunotoxicology at the faculty of Veterinary Medicine, Utrecht University in close collaboration with the National Institute for Public Health and the Environment (RIVM) in Bilthoven, The Netherlands.